Division of Infectious Diseases, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
Yonsei Med J. 2022 Dec;63(12):1078-1087. doi: 10.3349/ymj.2022.0298.
The association between reactogenicity and immunogenicity of the ChAdOx1 nCOV-19 is controversial. We aimed to evaluate this association among South Korean healthcare workers (HCWs).
Participants received two doses of the ChAdOx1vaccine 12 weeks apart. Blood samples were tested for anti-severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spike protein receptor binding domain antibodies about 2 months after the first and second doses using the Elecsys Anti-SARS-CoV-2 S assay kits. Adverse events were noted using an online self-reporting questionnaire.
Among the 232 HCWs, pain (85.78% after the first dose vs. 58.62% after the second dose, <0.001) was the most prominent local reaction, and myalgia or fatigue (84.05% vs. 53.02%, <0.001) was the most prominent systemic reaction. The frequency of all adverse events was significantly reduced after the second dose. After the first dose, the anti-SARS-CoV-2 S showed significantly higher titer in the group with swelling, itching, fever, and nausea. Also, the anti-SARS-CoV-2 S titer significantly increased as the grade of fever (=0.007) and duration of fever (=0.026) increased; however, there was no significant correlation between immunogenicity and adverse event after the second dose. The group with pain after the first dose showed a greater increase in the anti-SARS-CoV-2 S difference between the second and first doses compared to the group without pain (542.2 U/mL vs. 363.8 U/mL, =0.037).
The frequency of adverse events occurring after the first dose of the ChAdOx1 was significantly reduced after the second dose. Interestingly, the elevation of anti-SARS-CoV-2 S titer was significantly increased in the group with pain after the first dose.
关于 ChAdOx1 nCOV-19 的反应原性和免疫原性之间的关联存在争议。本研究旨在评估韩国医护人员（HCWs）中这种关联。
参与者间隔 12 周接受两剂 ChAdOx1 疫苗。大约在第一和第二剂后 2 个月，使用 Elecsys Anti-SARS-CoV-2 S 检测试剂盒检测抗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白受体结合域抗体。使用在线自我报告问卷记录不良事件。
在 232 名 HCWs 中，疼痛（第一次剂量后为 85.78%，第二次剂量后为 58.62%，<0.001）是最明显的局部反应，肌痛或疲劳（84.05% vs. 53.02%，<0.001）是最明显的全身反应。第二次剂量后，所有不良事件的频率均显著降低。第一次剂量后，肿胀、瘙痒、发热和恶心的组抗 SARS-CoV-2 S 的滴度显著较高。此外，随着发热等级（=0.007）和发热持续时间（=0.026）的增加，抗 SARS-CoV-2 S 的滴度也显著增加；然而，第二次剂量后免疫原性与不良事件之间没有显著相关性。第一次剂量后疼痛组的抗 SARS-CoV-2 S 差异比无疼痛组增加更大（542.2 U/mL 比 363.8 U/mL，=0.037）。
第二次剂量后，第一次剂量 ChAdOx1 后不良事件的发生频率显著降低。有趣的是，第一次剂量后疼痛组的抗 SARS-CoV-2 S 滴度显著升高。
